Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol Ablation for Hypertrophic Obstructive Cardiomyopathy

16. listopadu 2026 aktualizováno: Ligang Ding

Patients with hypertrophic obstructive cardiomyopathy (HOCM) require septal reduction therapy to relieve left ventricular outflow tract obstruction (LVOTO). Septal myectomy is an open surgical procedure that resects hypertrophied septal myocardium to reduce outflow tract obstruction. However, it is associated with relatively substantial trauma. Some patients cannot tolerate surgery due to comorbidities or decline open-chest surgery.

Transcoronary alcohol ablation is a classic minimally invasive septal reduction therapy with a clinical history of nearly 30 years. Alcohol ablation induces myocardial injury via a chemical agent to reduce septal hypertrophy, widen the left ventricular outflow tract, lower the systolic pressure gradient, and improve clinical symptoms. It serves as a minimally invasive alternative to surgery. Nevertheless, the efficacy of this technique is highly dependent on the anatomical features of septal branches. Suboptimal outcomes may occur in some patients owing to variable septal branch anatomy. In addition, due to the high myocardial permeability of alcohol, atrioventricular block occurs in approximately 20% of patients after the procedure.

In recent years, transcoronary radiofrequency ablation has emerged as a novel minimally invasive septal reduction approach in clinical practice. For radiofrequency ablation, a microcatheter is advanced over a coronary guidewire into the septal branch. The proximal end of the guidewire is connected to a radiofrequency ablation generator, and myocardial ablation is delivered around the guidewire tip. Occlusion of the septal branch may further potentiate the ablative effect. This technique is less limited by anatomical variations of septal branches, features a shorter learning curve, and may have less impact on the conduction system. Compared with alcohol ablation, it enables more precise ablation with potentially superior safety. Both minimally invasive strategies achieve an obstruction relief rate exceeding 90%. To date, head-to-head data comparing the efficacy and safety profiles of these two minimally invasive therapies remain absent. Therefore, this randomized controlled trial is designed to compare the efficacy and safety of transcoronary alcohol ablation versus transcoronary radiofrequency ablation for hypertrophic obstructive cardiomyopathy.

You will be randomized in a 1:1 ratio to either the transcoronary alcohol ablation group or the transcoronary radiofrequency ablation group using a block randomization schedule. The probability of assignment to either group is 50%.

After randomization, cardiopulmonary exercise testing data, laboratory results and echocardiographic data will be collected at baseline, and the impact of cardiomyopathy on your quality of life will be assessed. Procedures in both groups will be performed by designated operators of the study team following standardized protocols. You will be blinded to the assigned treatment. In both groups, SonoVue will be injected into the coronary septal branch intraoperatively, and transthoracic echocardiography will be used to confirm that the ablation target is the critical site responsible for obstruction to ensure precise treatment. In the alcohol ablation group, 2-3 mL of absolute alcohol will be injected into the septal branch. In the radiofrequency ablation group, the guidewire will be connected to the radiofrequency generator; ablation energy will be set at 30-40 W, with 3 ablation applications of 30 seconds each at a single target site. Intraoperative electrocardiogram, heart rate, blood pressure and symptoms will be closely monitored, and the pressure gradient will be measured in real time using catheters and ultrasound. All patients will receive standardized medical therapy after the procedure. You will attend an outpatient follow-up visit at 3 months post-procedure, where repeat cardiopulmonary exercise testing, laboratory tests and echocardiography will be performed, and the post-procedure impact of cardiomyopathy on your quality of life will be re-evaluated. The primary endpoint of this study is the improvement in peak oxygen consumption on cardiopulmonary exercise testing at 3 months after treatment. No blood or tissue samples will be collected or stored for this study.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

80

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína, 100037
        • Nábor
        • Fuwai Hospital, Chinese Academy of Medical Sciences
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • 1. Age > 18 years; 2. Diagnosis of hypertrophic obstructive cardiomyopathy (HOCM), with resting LVOTG > 50 mmHg measured by echocardiography or cardiac catheterization; 3. Persistent symptoms despite treatment with maximally tolerated doses of beta-blockers or calcium channel blockers (CCBs); 4. New York Heart Association (NYHA) functional class II or higher; 5. Echocardiographic confirmation that the obstruction originates from the interventricular septum at the left ventricular outflow tract; 6. Suitable septal branch visualized on coronary angiography, with contrast echocardiography confirming its perfusion territory corresponds to the target ablation site; 7. Interventricular septal thickness < 30 mm; 8. High surgical risk or explicit patient refusal of septal myectomy; 9. Ability to understand the study purpose, voluntary participation, and provision of written informed consent.

Exclusion Criteria:

  • Patients with severe mitral regurgitation secondary to organic mitral valve disease or other cardiac structural abnormalities requiring surgical intervention; Patients with significant stenosis of the left anterior descending coronary artery requiring percutaneous coronary intervention; Patients with bradyarrhythmia who have an indication for permanent pacemaker implantation; Patients with prior history of septal reduction therapy; Patients receiving myosin inhibitor therapy; Patients with severe hepatic or renal dysfunction; Patients with contraindications to coronary angiography and percutaneous interventional procedures; Patients with severe heart failure or cardiogenic shock who cannot maintain a supine position; Patients with a history of anaphylactic shock induced by contrast media; Patients considered ineligible for enrollment for other reasons at the investigator's discretion; Patients with pre-existing complete left bundle branch block at baseline.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: transcoronary radiofrequency ablation

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVO

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVOT

Ostatní jména:
  • TCRFA
Aktivní komparátor: transcoronary alcohol ablation

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

Ostatní jména:
  • asa

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
absolute improvement in peak VO₂
Časové okno: baseline,3 months

Cardiopulmonary exercise testing is performed at baseline and at 3 months after the procedure to measure peak VO₂. The absolute improvement in peak VO₂ is defined as the post-procedure value minus the baseline value.

baseline,3 months
ncidence of new-onset complete left or right bundle branch block and/or permanent pacemaker implantation
Časové okno: baseline,3 months

The incidence of new-onset complete left bundle branch block, complete right bundle branch block, and/or permanent pacemaker implantation occurring from the time of the index procedure up to the 3-month post-procedure follow-up.

baseline,3 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Intraprocedural immediate reduction of LVOTG meeting criteria for obstruction relief
Časové okno: Intraoperatively

Proportion of participants with immediate intraprocedural LVOTG reduction that satisfies the predefined criteria for relief of left ventricular outflow tract obstruction.

Intraoperatively
Response rate of peak VO₂ at 3 months post-procedure
Časové okno: Baseline and 3 months after the procedure

Response rate is defined as the proportion of participants achieving a predefined improvement in peak VO₂ measured by cardiopulmonary exercise testing at 3 months post-procedure versus baseline.

Baseline and 3 months after the procedure
Reduction of LVOTG meeting obstruction relief criteria at 3 months post-procedure
Časové okno: Baseline and 3 months after the procedure

Proportion of participants whose LVOTG reduction meets the predefined obstruction relief criteria at 3-month follow-up.

Baseline and 3 months after the procedure
Absolute reduction of basal septal thickness
Časové okno: Baseline and 3 months after the procedure

Absolute difference in basal interventricular septal thickness between baseline and 3 months post-procedure, assessed by echocardiography.

Baseline and 3 months after the procedure
6-minute walk test distance
Časové okno: Baseline and 3 months after the procedure

Distance covered during the 6-minute walk test at baseline and at 3 months post-procedure.

Baseline and 3 months after the procedure
Canadian Cardiovascular Society (CCS) Angina Grade
Časové okno: Baseline and 3 months after the procedure

Change in Canadian Cardiovascular Society angina grade from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Quality of life score
Časové okno: Baseline and 3 months after the procedure

Change in generic quality-of-life score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Časové okno: Baseline and 3 months after the procedure

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Improvement in New York Heart Association (NYHA) functional class
Časové okno: Baseline and 3 months after the procedure

Proportion of participants with improvement in New York Heart Association functional class at 3 months post-procedure compared with baseline.

Baseline and 3 months after the procedure

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

16. listopadu 2026

Primární dokončení (Odhadovaný)

30. září 2027

Dokončení studie (Odhadovaný)

31. prosince 2027

Termíny zápisu do studia

První předloženo

16. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

16. listopadu 2026

První zveřejněno (Aktuální)

20. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2025-2753

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Individual participant data will not be shared to ensure patient confidentiality and comply with local institutional data protection policies.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .